Chronic inflammatory demyelinating polyneuropathy or CIDP is a neurological disorder in which the body immune system attacks myelin which is a vital part of the nervous system. It occurs when the body immune system cannot distinguish between the body’s own cell and foreign cell and instead start destroying the healthy cells of the body. It is also known as chronic relapsing polyneuropathy. This can cause impaired ability, pain, loss of sensation, chronic fatigue and other problems, Different treatments can be used to treat the disease for instance intravenous immunoglobulin, physiotherapy, plasmapheresis, and others.
Some of the symptoms are both proximal and distal, orthostatic dizziness, initial limb weakness, tingling and numbness of hands & feet.
According to study, “Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Information By Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis (Plasma Exchange), Physiotherapy, Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, Others), By Route of Administration (Intravenous, Oral, Others), By End User (Hospitals, Specialty Neurological Clinics, Research & Academic Laboratories, Others) and Top Regions Forecast till 2023” the key companies operating in the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market are Octapharma AG, Shire, Kedrion S.p.A, Mitsubishi Tanabe Pharma Corporation, Grifols, Baxter, Momenta Pharmaceuticals Inc., Argenx SE, Immupharma Plc., Pfizer Inc., GeNeuro SA, Teijin Pharma Ltd, Takeda Pharmaceutical Co Ltd., UCB SA.
Based on treatment, Chronic Inflammatory Demyelinating Polyneuropathy market is segmented into intravenous immunoglobulin (IVIG), plasmapheresis (plasma exchange), corticosteroids, physiotherapy and others. IVIG segment dominates the market owing to its preference as the first line of treatment against CIDP. Based on diagnosis, market is segmented into electro-diagnostic testing, EMG, nerve conduction, spinal fluid analysis and others. Based on route of administration, market is segmented into oral, intravenous and others. Based on distribution channel, market is segmented into retail pharmacy, hospital pharmacy and online pharmacy. In addition, based on end-user, market is segmented into hospitals, research & academic laboratories, specialty neurological clinics and others.
The Chronic Inflammatory Demyelinating Polyneuropathy market is driven by rise in research & development (R&D) related to plasma-derived medicines, followed by growth in prevalence of autoimmune diseases, rise in government support via awareness programs & drug approvals and increase in awareness about Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). However, high cost of the IVIG treatment and side-effects associated with the IVIG treatment such as hypotension, lower back pain, flushing, nausea, chills, wheezing, etc. may impact the market. Moreover, growth in advancements in the treatment is a key opportunity for market.
Based on geography, the North-American region holds major share, followed by European region in Chronic Inflammatory Demyelinating Polyneuropathy market owing to growth in healthcare infrastructure and active government support in the region. The Asian-Pacific region is anticipated to witness lucrative growth rate due to rise in emphasis by healthcare organizations & government over the forecast period. It is projected that the market will be reached at rapid pace on account of high population & growth in per capita healthcare spending and increase the prevalence rate of CIDP during the forecast period. The market is developing at a CAGR of 6.2% and is estimated to reach US $3907.17 million by the end of the forecast period 2018-2023.
To know more, click on the link below:-
Ankur Gupta, Head Marketing & Communications